Impact of ovarian stimulation on corpus luteum function and embryonic implantation

被引：92

作者：

Tavaniotou, A ^{[1
]}

Albano, C ^{[1
]}

Smitz, J ^{[1
]}

Devroey, P ^{[1
]}

机构：

[1] Free Univ Brussels, Ctr Reprod Med, B-1090 Brussels, Belgium

来源：

JOURNAL OF REPRODUCTIVE IMMUNOLOGY | 2002年 / 55卷 / 1-2期

关键词：

corpus luteum; endometrial biopsy; ovarian stimulation; luteinizing hormone; luteal phase; in-vitro fertilization; gonadotrophin-releasing hormone;

D O I：

10.1016/S0165-0378(01)00134-6

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The luteal phase has been found to be defective in virtually all the stimulation protocols used in in-vitro fertilization (IVF), indicating that common mechanisms might be involved despite the use of different drugs. A normal luteal phase is characterised by a normal hormonal environment, normal progesterone secretion by the corpus luteum and adequate endometrial secretory transformation. Luteinizing hormone supports the corpus luteum and luteal luteinizing hormone (LH) levels have been found to be reduced in human menopausal gonadotrophin (HMG), gonadotrophin-releasing hormone (GnRH)-agonist/HMG and GnRH-antagonist/HMG protocols, probably leading to an insufficient corpus luteum function. Supraphysiological steroid serum concentrations routinely observed in stimulated cycles may adversely affect LH secretion and induce a luteal-phase defect. In turn, these high steroid serum concentrations may advance early luteal-phase endometrial development leading to embryo-endometrial asynchrony and decreased pregnancy rates in IVF cycles. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.

引用

页码：123 / 130

页数：8

共 28 条

[21] PITUITARY GONADOTROPIN SECRETORY CAPACITY DURING THE LUTEAL PHASE IN SUPEROVULATION USING GNRH-AGONISTS AND HMG IN A DESENSITIZATION OR FLARE-UP PROTOCOL [J].

SMITZ, J ;

ERARD, P ;

CAMUS, M ;

DEVROEY, P ;

TOURNAYE, H ;

WISANTO, A ;

VANSTEIRTEGHEM, AC .

HUMAN REPRODUCTION, 1992, 7 (09) :1225-1229

[22] THE LUTEAL PHASE AND EARLY-PREGNANCY AFTER COMBINED GNRH-AGONIST HMG TREATMENT FOR SUPEROVULATION IN IVF OR GIFT [J].

SMITZ, J ;

DEVROEY, P ;

CAMUS, M ;

DESCHACHT, J ;

KHAN, I ;

STAESSEN, C ;

VANWAESBERGHE, L ;

WISANTO, A ;

VANSTEIRTEGHEM, AC .

HUMAN REPRODUCTION, 1988, 3 (05) :585-590

[23] PROGESTERONE MODULATION OF PULSATILE LUTEINIZING-HORMONE SECRETION IN NORMAL WOMEN [J].

SOULES, MR ;

STEINER, RA ;

CLIFTON, DK ;

COHEN, NL ;

AKSEL, S ;

BREMNER, WJ .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1984, 58 (02) :378-383

[24]

SPEROFF L, 1994, CLIN ENDOCRINOLOGY I, P213

[25]

STERZIK K, 1988, FERTIL STERIL, V50, P457

[26] Comparison of LH concentrations in the early and midluteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix [J].

Tavaniotou, A ;

Albano, C ;

Smitz, J ;

Devroey, P .

HUMAN REPRODUCTION, 2001, 16 (04) :663-667

[27] Endometrial evaluation by aspiration biopsy on the day of oocyte retrieval in the embryo transfer cycles in patients with serum progesterone rise during the follicular phase [J].

Ubaldi, F ;

Bourgain, C ;

Tournaye, H ;

Smitz, J ;

VanSteirteghem, A ;

Devroey, P .

FERTILITY AND STERILITY, 1997, 67 (03) :521-526

[28] PROGESTERONE SYNTHESIS BY HUMAN LUTEAL CELLS - MODULATION BY ESTRADIOL [J].

VEGA, M ;

DEVOTO, L ;

CASTRO, O ;

KOHEN, P .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 79 (02) :466-469

← 1 2 3 →